HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

capadenoson

Also Known As:

BAY-68-4986

Networked: 12 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aminopyridines: 77
    - capadenoson: 12
- Sulfur Compounds: 278
  - Thiazoles: 392
    - capadenoson: 12
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - capadenoson: 12
  - Pyridines: 88
    - Aminopyridines: 77
      - capadenoson: 12

Experts

1.	Christopoulos, Arthur: 3 articles (01/2021 - 01/2016)
2.	May, Lauren T: 3 articles (01/2021 - 01/2016)
3.	White, Paul J: 3 articles (01/2021 - 01/2016)
4.	Sexton, Patrick M: 2 articles (01/2021 - 01/2016)
5.	Baltos, Jo-Anne: 2 articles (01/2017 - 01/2016)
6.	Zimmermann, Katja: 2 articles (05/2013 - 03/2011)
7.	Balzulat, Annika: 1 article (01/2021)
8.	Charman, William N: 1 article (01/2021)
9.	Chimenti, Stefano: 1 article (01/2021)
10.	Feletou, Michel: 1 article (01/2021)

Related Diseases

1.	Stable Angina 07/01/2012 - "In patients with stable angina capadenoson lowers exercise HR at comparable maximum workload, which is associated with improved total exercise time and prolongation of time to ischaemia." 07/01/2012 - "The present proof-of-concept study aimed at evaluation of the efficacy and safety of a new adenosine A1 receptor agonist capadenoson in patients with stable angina. " 07/01/2012 - "The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina." 01/01/2017 - "Capadenoson, currently classified as an adenosine A1 receptor (A1AR) partial agonist, has undergone two Phase IIa clinical trials, initially in patients with atrial fibrillation and subsequently in patients with stable angina. "
2.	Heart Failure 10/01/2020 - "For the human adenosine A1 receptor (hA1AR) this has led to the discovery of capadenoson, which has been in phase IIa clinical trials for heart failure. " 05/01/2013 - "This study examined the effects of capadenoson (CAP), a partial adenosine A1-receptor agonist, on left ventricular (LV) function and remodeling in dogs with heart failure. " 01/01/2017 - "Capadenoson has also been shown to decrease cardiac remodeling in an animal model of advanced heart failure and a capadenoson derivative, neladenoson bialanate, recently entered clinical development for the treatment of chronic heart failure. " 01/01/2021 - "We compare this agent with the well-characterized, pan-adenosine receptor (AR) agonist NECA, capadenoson, and the A1R biased agonist VCP746, previously shown to be safe and cardioprotective in pre-clinical models of heart failure. "
3.	Atrial Fibrillation 01/01/2017 - "Capadenoson, currently classified as an adenosine A1 receptor (A1AR) partial agonist, has undergone two Phase IIa clinical trials, initially in patients with atrial fibrillation and subsequently in patients with stable angina. " 05/01/2011 - "Other selective agonists and antagonists are or were undergoing clinical trials for a broad range of indications, including capadenoson and tecadenoson (A(1) agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, respectively, apadenoson and binodenoson (A(2A) agonists) for myocardial perfusion imaging, preladenant (A(2A) antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A(3) agonists) for inflammatory diseases and cancer, respectively."
4.	Ventricular Tachycardia 05/01/2011 - "Other selective agonists and antagonists are or were undergoing clinical trials for a broad range of indications, including capadenoson and tecadenoson (A(1) agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, respectively, apadenoson and binodenoson (A(2A) agonists) for myocardial perfusion imaging, preladenant (A(2A) antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A(3) agonists) for inflammatory diseases and cancer, respectively."
5.	Parkinson Disease (Parkinson's Disease) 05/01/2011 - "Other selective agonists and antagonists are or were undergoing clinical trials for a broad range of indications, including capadenoson and tecadenoson (A(1) agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, respectively, apadenoson and binodenoson (A(2A) agonists) for myocardial perfusion imaging, preladenant (A(2A) antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A(3) agonists) for inflammatory diseases and cancer, respectively."

Related Drugs and Biologics

1.	Adenosine A1 Receptor
2.	tecadenoson
3.	Adenosine (Adenocard)
4.	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amine
5.	CF101
6.	binodenoson
7.	VCP746
8.	Purinergic P1 Receptor Antagonists
9.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
10.	Purinergic P1 Receptors (Adenosine Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Pain Management